Description

Thymosin Enteric?Coated Tablets (LeSaiXian) contain 10?mg of thymosin peptide per tablet in an enteric-coated oral formulation designed to resist stomach acid degradation. This patented immune?modulating peptide has been studied for enhancing T?cell mediated immunity, regulating cytokine responses, and supporting immune homeostasis in experimental models. Manufactured under license H20073462 by Heilongjiang Dilong Pharmaceutical Co., Ltd., this product offers reliable dosage precision and bioavailability suitable for laboratory and preclinical research. Each box contains 24 enteric tablets. For research use only.

Product Specifications

Mechanism of Action & Research Applications

Thymosin Enteric?Coated Tablets (LeSaiXian) release the thymosin peptide in the intestine, bypassing stomach acid to enhance bioavailability. Thymosin peptides modulate immune response by promoting T?cell differentiation and activation, balancing Th1/Th2 cytokines, enhancing NK and dendritic cell function, and restoring immune homeostasis. In laboratory research, LeSaiXian tablets are used to study immune modulation in models of immunodeficiency, viral infection, autoimmune disease, and vaccine adjuvant response. Ideal for experiments on immune system regulation and peptide therapy. For research use only.

Side Effects (For Reference Only in Models)

In experimental models, possible side effects may include mild gastrointestinal discomfort, skin reactions, transient fever, fatigue, or injection?site-like responses in oral peptide models. Overstimulation of immune activity is rare but should be monitored in dose escalation studies. These references are intended for research model design and safety monitoring.

Disclaimer

Thymosin Enteric?Coated Tablets (LeSaiXian) are strictly intended for laboratory research use only. Not for human or veterinary therapeutic use.